Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database

Novo Nordisk logo

Novo Nordisk

Status

Completed

Conditions

Haemophilia B
Haemophilia A
Congenital Bleeding Disorder

Treatments

Drug: activated recombinant human factor VII

Study type

Observational

Funder types

Industry

Identifiers

NCT00853086
F7HAEM-3537
U1111-1130-5940 (Other Identifier)

Details and patient eligibility

About

This study is conducted in Europe. The purpose of this retrospective study is to collect additional safety information of patients with haemophilia and inhibitors who are treated with rFVIIa.

Full description

Non-interventional, retrospective data collection on standard treatments of haemophilia A and B patients with inhibitors in the UK.

Enrollment

139 patients

Sex

Male

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All haemophilia A or B patients with inhibitors treated with NovoSeven are included

Exclusion criteria

  • No exclusion criteria beyond the contraindications described in the approved product information text

Trial design

139 participants in 1 patient group

A
Treatment:
Drug: activated recombinant human factor VII

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems